These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 35563420)
21. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates. Moriarty TF; Elborn JS; Tunney MM Br J Biomed Sci; 2007; 64(3):101-4. PubMed ID: 17910277 [TBL] [Abstract][Full Text] [Related]
22. Exopolysaccharide-Repressing Small Molecules with Antibiofilm and Antivirulence Activity against Pseudomonas aeruginosa. van Tilburg Bernardes E; Charron-Mazenod L; Reading DJ; Reckseidler-Zenteno SL; Lewenza S Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223377 [TBL] [Abstract][Full Text] [Related]
23. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa. Soren O; Rineh A; Silva DG; Cai Y; Howlin RP; Allan RN; Feelisch M; Davies JC; Connett GJ; Faust SN; Kelso MJ; Webb JS J Antimicrob Chemother; 2020 Jan; 75(1):117-125. PubMed ID: 31682251 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria. Strateva T; Petrova G; Mitov I J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744 [TBL] [Abstract][Full Text] [Related]
25. Cell-free supernatants from Lactobacillus strains exert antibacterial, antibiofilm, and antivirulence activity against Pseudomonas aeruginosa from cystic fibrosis patients. Pompilio A; Kaya E; Lupetti V; Catelli E; Bianchi M; Maisetta G; Esin S; Di Bonaventura G; Batoni G Microbes Infect; 2024; 26(4):105301. PubMed ID: 38237656 [TBL] [Abstract][Full Text] [Related]
26. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. Kirchner S; Fothergill JL; Wright EA; James CE; Mowat E; Winstanley C J Vis Exp; 2012 Jun; (64):e3857. PubMed ID: 22711026 [TBL] [Abstract][Full Text] [Related]
27. Characterizations of the viability and gene expression of dispersal cells from Pseudomonas aeruginosa biofilms released by alginate lyase and tobramycin. Daboor SM; Raudonis R; Cheng Z PLoS One; 2021; 16(10):e0258950. PubMed ID: 34695148 [TBL] [Abstract][Full Text] [Related]
28. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. Pompilio A; Crocetta V; Scocchi M; Pomponio S; Di Vincenzo V; Mardirossian M; Gherardi G; Fiscarelli E; Dicuonzo G; Gennaro R; Di Bonaventura G BMC Microbiol; 2012 Jul; 12():145. PubMed ID: 22823964 [TBL] [Abstract][Full Text] [Related]
29. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation. Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004 [TBL] [Abstract][Full Text] [Related]
30. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor. Furiga A; Lajoie B; El Hage S; Baziard G; Roques C Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774 [TBL] [Abstract][Full Text] [Related]
31. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase). Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442 [TBL] [Abstract][Full Text] [Related]
32. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Anderson GG; Moreau-Marquis S; Stanton BA; O'Toole GA Infect Immun; 2008 Apr; 76(4):1423-33. PubMed ID: 18212077 [TBL] [Abstract][Full Text] [Related]
33. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647 [TBL] [Abstract][Full Text] [Related]
34. Anti-Virulence Potential of a Chionodracine-Derived Peptide against Multidrug-Resistant Artini M; Imperlini E; Buonocore F; Relucenti M; Porcelli F; Donfrancesco O; Tuccio Guarna Assanti V; Fiscarelli EV; Papa R; Selan L Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362282 [No Abstract] [Full Text] [Related]
35. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Pompilio A; Scocchi M; Pomponio S; Guida F; Di Primio A; Fiscarelli E; Gennaro R; Di Bonaventura G Peptides; 2011 Sep; 32(9):1807-14. PubMed ID: 21849157 [TBL] [Abstract][Full Text] [Related]
36. Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics. Daboor SM; Rohde JR; Cheng Z J Cyst Fibros; 2021 Mar; 20(2):264-270. PubMed ID: 32482592 [TBL] [Abstract][Full Text] [Related]
37. Polymyxin B and ethylenediaminetetraacetic acid act synergistically against Hale SJM; Cameron AJ; Lux CA; Biswas K; Kim R; O'Carroll M; Harris PWR; Douglas RG; Wagner Mackenzie B Microbiol Spectr; 2024 Feb; 12(2):e0170923. PubMed ID: 38168683 [TBL] [Abstract][Full Text] [Related]
38. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Moreau-Marquis S; O'Toole GA; Stanton BA Am J Respir Cell Mol Biol; 2009 Sep; 41(3):305-13. PubMed ID: 19168700 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226 [TBL] [Abstract][Full Text] [Related]
40. Anti-Persisters Activity of Bianchi M; Esin S; Kaya E; Batoni G; Maisetta G Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000222 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]